M. Arango

发表

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Shinji Yamazaki, J. Christensen, B. Mroczkowski, 2007, Molecular Cancer Therapeutics.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Shinji Yamazaki, Gordon Alton, Pei-Pei Kung, 2007, Cancer research.

Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy

P. O'Connor, S. Bender, B. Jessen, 2008, Molecular Cancer Therapeutics.

Production and localization of Muc4/sialomucin complex and its receptor tyrosine kinase ErbB2 in the rat lacrimal gland.

C. A. Carraway, M. Arango, M. Komatsu, 2001, Investigative ophthalmology & visual science.

Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive.

C. A. Carraway, K. Carraway, M. Arango, 2002, Progress in nucleic acid research and molecular biology.

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

J. Christensen, S. Bender, K. Zasadny, 2010, Clinical Cancer Research.

Fully Human Monoclonal Antibody against R adherin with Antitumor and Antimetastatic Activity

J. Christensen, S. Bender, K. Zasadny, 2010 .

PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

J. Christensen, K. Zasadny, Guizhen Sun, 2009, Clinical Cancer Research.

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

P. O'Connor, A. Blasina, J. Register, 2008, Molecular Cancer Therapeutics.

Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor

Masanobu Komatsu, C. A. Carraway, K. Carraway, 2001, Oncogene.

Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

P. Rudland, L. Yee, K. Carraway, 2002, International journal of cancer.

Expression and localization of immunoreactive-sialomucin complex (Muc4) in salivary glands.

C. Reis, M. Arango, K. Carraway, 2001, Tissue & cell.

Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways

C. A. Carraway, K. Carraway, M. Arango, 2002, Oncogene.

Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis.

K. Carraway, M. Arango, M. Komatsu, 2002, The Biochemical journal.

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Shinji Yamazaki, Tod Smeal, J. Christensen, 2012, Molecular Cancer Therapeutics.

Preclinical Development Sensitivity ofSelectedHumanTumorModels toPF-04217903 , a Novel Selective c-Met Kinase Inhibitor

J. Christensen, J. Cui, M. McTigue, 2012 .

Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models

K. Anderes, C. Painter, M. Arango, 2009, Clinical Cancer Research.

An ErbB2-Muc4 complex in rat ocular surface epithelia

C. A. Carraway, K. Carraway, M. Arango, 2002, Current eye research.

Differential 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models

J. Christensen, B. Solomon, D. Binns, 2011, The Journal of Nuclear Medicine.

AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo

Gennady M Verkhivker, D. Knighton, C. Lewis, 2005 .

AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity